HU9700598D0 - Process for profilacting and treating pancreatitis - Google Patents

Process for profilacting and treating pancreatitis

Info

Publication number
HU9700598D0
HU9700598D0 HU9700598A HUP9700598A HU9700598D0 HU 9700598 D0 HU9700598 D0 HU 9700598D0 HU 9700598 A HU9700598 A HU 9700598A HU P9700598 A HUP9700598 A HU P9700598A HU 9700598 D0 HU9700598 D0 HU 9700598D0
Authority
HU
Hungary
Prior art keywords
profilacting
treating pancreatitis
pancreatitis
treating
troglitazone
Prior art date
Application number
HU9700598A
Other languages
English (en)
Inventor
Toshihiko Fujiwara
Seiji Fukami
Hiroyoshi Horikoshi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of HU9700598D0 publication Critical patent/HU9700598D0/hu
Publication of HUP9700598A2 publication Critical patent/HUP9700598A2/hu
Publication of HUP9700598A3 publication Critical patent/HUP9700598A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Catching Or Destruction (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9700598A 1996-03-18 1997-03-17 Process for producing pharmaceutical composition useful for profilacting and treating pancreatitis HUP9700598A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6106396 1996-03-18
JP25020196 1996-09-20

Publications (3)

Publication Number Publication Date
HU9700598D0 true HU9700598D0 (en) 1997-05-28
HUP9700598A2 HUP9700598A2 (hu) 1998-09-28
HUP9700598A3 HUP9700598A3 (en) 1998-10-28

Family

ID=26402115

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700598A HUP9700598A3 (en) 1996-03-18 1997-03-17 Process for producing pharmaceutical composition useful for profilacting and treating pancreatitis

Country Status (19)

Country Link
US (1) US5753681A (hu)
EP (1) EP0796618B1 (hu)
KR (1) KR100542778B1 (hu)
CN (1) CN1178657C (hu)
AT (1) ATE212548T1 (hu)
AU (1) AU708315B2 (hu)
CA (1) CA2200126C (hu)
CZ (1) CZ283968B6 (hu)
DE (1) DE69710111T2 (hu)
DK (1) DK0796618T3 (hu)
ES (1) ES2167678T3 (hu)
HK (1) HK1003051A1 (hu)
HU (1) HUP9700598A3 (hu)
ID (1) ID16266A (hu)
IL (1) IL120443A (hu)
NO (1) NO313179B1 (hu)
NZ (1) NZ314406A (hu)
PT (1) PT796618E (hu)
TW (1) TW548102B (hu)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711683D0 (en) * 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
KR100666887B1 (ko) * 1997-10-08 2007-01-10 상꾜 가부시키가이샤 치환 축합 복소환 화합물
DE69914557T2 (de) * 1998-03-30 2005-01-05 Japan Tobacco Inc. Verfahren zur herstellung einer isooxazolidindion-verbindung
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
JP4533534B2 (ja) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド グリコーゲンシンターゼキナーゼ３のインヒビター
AP2001002036A0 (en) * 1998-07-21 2001-03-31 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing apoptosis.
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
WO2001000223A2 (en) * 1999-06-25 2001-01-04 Minimed Inc. Multiple agent diabetes therapy
CN1167691C (zh) 1999-08-23 2004-09-22 杏林制药株式会社 取代的苄基噻唑烷-2,4-二酮衍生物
ATE296294T1 (de) 1999-08-23 2005-06-15 Kyorin Seiyaku Kk Substituierte benzylthiazolidin-2,4-dion-derivate
US6452014B1 (en) * 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US6852694B2 (en) 2001-02-21 2005-02-08 Medtronic Minimed, Inc. Stabilized insulin formulations
US6737401B2 (en) * 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
CA2752908A1 (en) 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4703052A (en) * 1985-05-21 1987-10-27 Pfizer Inc. Hypoglycemic thiazolidinediones
US5232925A (en) * 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5260445A (en) * 1987-09-04 1993-11-09 Beecham Group P.L.C. 2,4-thiazolidinediones
EP0842925A1 (en) * 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
US5194443A (en) * 1987-09-04 1993-03-16 Beecham Group P.L.C. Compounds
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
ZA895838B (en) * 1988-08-18 1991-03-27 Syntex Inc Pharmaceutical compounds
JP2845743B2 (ja) * 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
AU7118694A (en) * 1993-07-13 1995-02-13 Janica M. Moizis Fastener for clothing
KR0164665B1 (ko) * 1993-12-27 1999-01-15 미즈노 시게루 이소옥사졸리딘디온 유도체 및 그의 용도
CZ289317B6 (cs) * 1994-04-11 2002-01-16 Sankyo Company Limited Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
FR2721608B1 (fr) * 1994-06-22 1996-07-19 Rhone Poulenc Rorer Sa Dérivés de thiazolidine, leur préparation et les médicaments les contenant.
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5703096A (en) * 1994-10-07 1997-12-30 Sankyo Company, Limited Oxime derivatives, their preparation and their therapeutic use
IL118474A (en) * 1995-06-01 2001-08-08 Sankyo Co Benzimideol derivatives and pharmaceutical preparations containing them

Also Published As

Publication number Publication date
AU708315B2 (en) 1999-07-29
ES2167678T3 (es) 2002-05-16
US5753681A (en) 1998-05-19
HUP9700598A2 (hu) 1998-09-28
MX9702058A (es) 1998-03-31
DE69710111D1 (de) 2002-03-14
CA2200126A1 (en) 1997-09-18
ATE212548T1 (de) 2002-02-15
IL120443A (en) 2000-07-16
EP0796618B1 (en) 2002-01-30
CZ283968B6 (cs) 1998-07-15
NO971219D0 (no) 1997-03-17
CN1170575A (zh) 1998-01-21
CN1178657C (zh) 2004-12-08
DE69710111T2 (de) 2002-10-02
DK0796618T3 (da) 2002-05-06
PT796618E (pt) 2002-06-28
ID16266A (id) 1997-09-18
NZ314406A (en) 2000-12-22
KR100542778B1 (ko) 2006-04-14
IL120443A0 (en) 1997-07-13
KR19980023975A (ko) 1998-07-06
NO971219L (no) 1997-09-19
HK1003051A1 (en) 1998-10-09
NO313179B1 (no) 2002-08-26
TW548102B (en) 2003-08-21
HUP9700598A3 (en) 1998-10-28
AU1628597A (en) 1997-09-25
CA2200126C (en) 2006-08-15
CZ79097A3 (en) 1997-10-15
EP0796618A1 (en) 1997-09-24

Similar Documents

Publication Publication Date Title
HU9700598D0 (en) Process for profilacting and treating pancreatitis
EP0908186A3 (en) Method for treating pain
HRP950288A2 (en) Oxalylamino-benzofuran- and benzothienyl-derivatives
AU1645995A (en) Leather treatment process for leather coloring, leather coloring process performed on leather thereby treated, and leather article produced by the leather coloring process
AU6452194A (en) Pharmaceutical agents for treatment of emesis
ZA943787B (en) Aromatic acetylcholinesterase inhibitors
EP0684951A1 (en) SILYL ACETYLCHOLINESTERASE INHIBITORS.
WO2000021513A3 (en) Methods for treating multiple sclerosis
AU1587595A (en) Process for the treatment of contaminated material
ZA969925B (en) Composition for treating stains on laundry items and methods of treatment.
AU3187595A (en) Compounds for the treatment of restenosis
EP0630383A4 (en) METHODS OF TREATING DIABETES.
NO944340D0 (no) Melatoninderivater for anvendelse ved behandling av desynkroniseringstilstander
AU1587495A (en) Process for the treatment of contaminated land
NZ511997A (en) Isonipecotamides for the treatment of integrin-mediated disorders
MX9704035A (es) 1,1-dioxidos de 2-(fosfiniloximetil)-1,2,5-tiadiazolidin-3-ona substituidos y composiciones y metodo de uso de los mismos.
EP0610669A3 (de) Vorrichtung zum Behandeln von Körperteilen mit Vibrationen.
MX9704036A (es) 1,1-dioxidos y composiciones de 2-(2,3,5,6-tetrafluoro-4-piridil)-1,2,5-thiadizaolidin-3-ona y metodo de uso.
EP0950411B8 (de) Verfahren zur Herstellung eines Extraktes aus Copalchirinde und Verwendung der Neoflavonoide zur Behandlung von Diabetes
EP0646651A3 (en) Method for improving the treatment of leather.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
EP0626379A3 (de) Verfahren zur Herstellung von 2-Chlor-benzothiazolen oder 2-Chlor-benzoxazolen.
EP0643123A3 (en) Process for the treatment of halogenated hydrocarbons.
HUT67823A (en) Process for the production of leather treating substance from environment-damaging, protein sewage
WO2000007582A3 (en) Use of thiazolidinedione derivatives for the treatment or prevention of cataracts

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished